Acknowledgement
이 성과는 2017년도 정부(미래창조과학부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구(No. NRF-2017R1C1B2009057)와 농림축산식품부의 재원으로 농림수산식품기술기획평가원의 고부가가치식품기술개발사업의 지원을 받아서 연구되었음(No. 116015-03-1-CG000).
References
- Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 2016;5:e200.
- Anandavadivelan P, Lagergren P. Cachexia in patients with oesophageal cancer. Nat Rev Clin Oncol 2016;13(3):185-198
- Braun TP, Marks DL. Pathophysiology and treatment of inflammatory anorexia in chronic disease. J Cachexia Sarcopenia Muscle 2010;1(2):135-145.
- Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14(11):754-762.
- Crawford J. Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care 2016;19(3):199-204.
- Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia--pathophysiology and management. J Gastroenterol 2013;48(5):574-594.
- Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle 2014;5(2):83-87.
- Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS.Role of NF-kappa B and cytokine in experimental cancer cachexia. World J Gastroenterol 2003;9(7):1567-1570.
- Talbert EE, Metzger GA, He WA, Guttridge DC.Modeling human cancer cachexia in colon 26 tumor-bearing Adult mice. J Cachexia Sarcopenia Muscle 2014;5(4):321-328.
- Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle 2015;6(4):287-302.
- Murphy KT, Chee A, Treiu J, Naim T, Lynch GS. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech 2012;5(4):533-545.
- Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012;16(2):153-166.
- Gangadharan A, Choi SE, Hassan A, et al. Protein calorie malnutrition, nutritional intervention and personalized cancer care. Oncotarget 2017;8(14):24009-24030.
- Zhang HY, Zhang Q, Zhang X, et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011;300(3):454-460.
- Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol 2014;44(4):1032-1040.
- Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012;303(3):E410-421.
- Zimmers TA, Fishel ML, Bonetto A.STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol 2016;54:28-41.
- Belizario JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E. Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. Springerplus. 2016;5:619.
- Jang K, Yoon S, Kim SE. Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state. Drug Des Devel Ther 2014;8:851-858.
- Yae S, Takahashi F, Yae T, et al. Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice. Evid Based Complement Alternat Med. 2012;2012:976926.
- Iizuka N, Hazama S, Yoshimura K. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer 2002;99(2):286-291.